Beretta-Piccoli C, Salvadé G, Bachmann C, Riesen W, Zuppinger K
Ospedale Italiano, Viganello, Switzerland.
J Hum Hypertens. 1988 Aug;2(2):103-10.
Ketanserin is a serotonin S2 receptor antagonist with antihypertensive activity. Its effects on blood pressure, glucose metabolism and serum lipids were assessed in 24 patients with diabetes mellitus and mild arterial hypertension in a double blind, placebo-controlled trial. Ketanserin in doses up to 80 mg daily caused a slight decrease of supine BP (from 159/97 +/- 19/11 to 153/90 +/- 20/9 mm Hg; NS/P less than 0.01) and upright BP (from 160/102 +/- 18/13 to 151/93 +/- 12/12 mm Hg; P less than 0.05/NS). However, these pressures did not differ significantly from the levels observed in the placebo group. Supine and upright heart rate, body weight, plasma sodium and potassium, serum creatinine, glucose, C-peptide, glycosylated haemoglobin, serum cholesterol and triglycerides, their lipoprotein fractions, apolipoprotein A1, A2 and B concentrations and the responses of serum glucose and insulin to a standard oral glucose loading test did not change. These findings indicate that the selective S2 receptor antagonist ketanserin did not unfavourably influence glucose and lipid metabolism in diabetic patients with arterial hypertension.
酮色林是一种具有抗高血压活性的5-羟色胺S2受体拮抗剂。在一项双盲、安慰剂对照试验中，对24例糖尿病合并轻度动脉高血压患者评估了其对血压、糖代谢和血脂的影响。每日剂量高达80mg的酮色林使仰卧位血压略有下降（从159/97±19/11降至153/90±20/9mmHg；无显著性差异/ P<0.01），立位血压也略有下降（从160/102±18/13降至151/93±12/12mmHg；P<0.05/无显著性差异）。然而，这些血压与安慰剂组观察到的水平无显著差异。仰卧位和立位心率、体重、血浆钠和钾、血清肌酐、葡萄糖、C肽、糖化血红蛋白、血清胆固醇和甘油三酯、它们的脂蛋白组分、载脂蛋白A1、A2和B浓度以及血清葡萄糖和胰岛素对标准口服葡萄糖负荷试验的反应均未改变。这些发现表明，选择性S2受体拮抗剂酮色林对合并动脉高血压的糖尿病患者的糖脂代谢没有不利影响。
